Synovial sarcoma is a rare, aggressive cancer with limited treatment options. Tecelra, the first T-cell receptor (TCR) gene therapy approved in the U.S., marks a major breakthrough by engineering patients’ T-cells to target tumor antigens. It has shown promising responses in advanced cases, offering new hope and advancing precision cancer therapy.

<h2>What Is Rhabdomyosarcoma?</h2><p><strong>Rhabdomyosarcoma (RMS)</strong> is the <strong>most common soft tissue sarcoma in children and adolescents</strong>, accounting for approximately <strong>3%–4% of all childhood cancers</strong> and approximately <strong>350 new cases per year</strong> in the United States. RMS arises from <strong>primitive mesenchymal cells</strong> that normally give rise to skeletal muscle, though it can occur in sites that lack skeletal muscle (